{"article_title": "For Biosimilars Under Medicare, It Is Just The Beginning", "article_keywords": ["products", "wake", "biosimilars", "drug", "medicaid", "york", "2015", "medicare", "biosimilar", "beginning", "view"], "article_url": "http://www.law360.com/articles/643951/for-biosimilars-under-medicare-it-is-just-the-beginning", "article_text": "For Biosimilars Under Medicare, It Is Just The Beginning\n\nLaw360, New York (April 16, 2015, 5:01 PM ET) -- On March 30, 2015, in the wake of the first biosimilar product licensed by the U.S. Food and Drug Administration, the Centers for Medicare and Medicaid Services issued several guidance documents addressing the treatment of biosimilar products under Medicare Part B, Medicare Part D and the Medicaid Drug Rebate Program.\n\n\n\nGenerally, because biosimilar products do not meet the definitions of \u201cgeneric\u201d or \u201cmultiple source\u201d drugs under either the Medicare or Medicaid programs, in part because biosimilars are approved via a biological license application, CMS will treat...\n\nTo view the full article, register now.", "article_metadata": {"description": "The U.S. Food and Drug Administration has yet to designate any biosimilar products as \u201cinterchangeable\u201d and, although the Centers for Medicare and Medicaid Services' position on the Medicaid Drug Rebate Program is broadly applicable to all biosimilars, it remains unclear whether CMS will treat all biosimilars equally under Medicare, say attorneys at King & Spalding LLP.", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/643951/for-biosimilars-under-medicare-it-is-just-the-beginning", "csrf-token": "lSZFpzoxbS75+qlCeDFOY/H7BlxWETIz0i5q5fadacZgvhh0CWxhW3FuwlU1KyUUsqn5gdEtzKPyjC95BCJzUg==", "csrf-param": "authenticity_token", "og": {"url": "http://www.law360.com/articles/643951/for-biosimilars-under-medicare-it-is-just-the-beginning", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "For Biosimilars Under Medicare, It Is Just The Beginning - Law360"}, "viewport": "width=device-width, initial-scale=1.0"}, "_id": "\"57477af46914bd0286fd80d1\"", "article_summary": "For Biosimilars Under Medicare, It Is Just The BeginningLaw360, New York (April 16, 2015, 5:01 PM ET) -- On March 30, 2015, in the wake of the first biosimilar product licensed by the U.S. Food and Drug Administration, the Centers for Medicare and Medicaid Services issued several guidance documents addressing the treatment of biosimilar products under Medicare Part B, Medicare Part D and the Medicaid Drug Rebate Program.\nGenerally, because biosimilar products do not meet the definitions of \u201cgeneric\u201d or \u201cmultiple source\u201d drugs under either the Medicare or Medicaid programs, in part because biosimilars are approved via a biological license application, CMS will treat...To view the full article, register now."}